Natixis Advisors LLC Has $3.91 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Natixis Advisors LLC trimmed its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 19.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,687 shares of the company's stock after selling 15,386 shares during the quarter. Natixis Advisors LLC owned about 0.19% of TransMedics Group worth $3,909,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMDX. Hager Investment Management Services LLC acquired a new stake in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC purchased a new position in TransMedics Group in the fourth quarter valued at approximately $40,000. AlphaQuest LLC acquired a new position in TransMedics Group during the fourth quarter valued at approximately $52,000. Quarry LP grew its stake in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after buying an additional 312 shares during the period. Finally, National Bank of Canada FI increased its position in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after acquiring an additional 262 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Performance

TMDX traded down $0.47 during trading on Wednesday, reaching $70.32. 867,692 shares of the company were exchanged, compared to its average volume of 1,303,087. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a 50 day moving average of $68.43 and a 200 day moving average of $89.16. The stock has a market cap of $2.37 billion, a P/E ratio of 74.81 and a beta of 2.12.

Remove Ads

Analyst Ratings Changes

Several brokerages recently commented on TMDX. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research note on Wednesday, December 11th. Robert W. Baird lowered their price objective on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday. Finally, Oppenheimer restated an "outperform" rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.